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Abstract
The aim of this study was to determine the efficacy of sublingual allergen-specific immunotherapy (SLIT) in Ukrainian 
children younger than 5 years old with allergic rhinitis and bronchial asthma sensitized to house dust mite allergens.
Material and methods: Four hundred and fifty children aged 28 months up to 5 years with rhinitis or asthma were examined. 
One hundred and twenty five children sensitized to house dust mites Dermatophagoides pteronyssinus and/or Dermatophagoides 
farina were included. In vivo and in vitro tests were made with a standard inhalant allergens panel.
Results: The high information value of molecular diagnostics methods applied prior to prescription of the given therapy in 
children is analyzed. It has been found that in children under 5 sensitized to allergens of house dust mites Dermatophagoides pter-
onyssinus and/or Dermatophagoides farinae the application of sublingual allergen-specific immunotherapy therapy allows gaining 
control over the symptoms of the disease during the first 6 months.
Conclusion: The high safety of SLIT in children has been proven. Comparative analysis in the group of patients not receiving 
SLIT shows a high frequency of symptoms of the disease after “free-of-symptoms interval” against full or partial baseline therapy denial.
Keywords: sublingual allergen-specific immunotherapy, children, Diater-Laboratories, bronchial asthma, allergic rhinitis, 
sensitization, allergens.
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1. Introduction
High frequency and advanced growth of the number of allergic diseases all over the world 
testifies to the need to further study of the problem that seems to have been well-studied. The 
search of new possibilities to diagnose and the related therapy methods constitutes a strategic task 
determined by WAO for the next decade. A feature of allergic diseases in children is the transfor-
mation of one form into the other. It is well-known that a special feature of the course of allergic 
diseases is age progression of allergy symptoms known in research literature as “atopic march”. 
Quite a number of papers are dedicated to the problem of “atopic march” diagnose, treatment and 
prevention in children [1–4]. However, today clinicians more and more frequently point out a paral-
lel course of several allergic diseases connected with a common total pathogenesis chain. This pro-
cess is characterized by relative instability of clinical allergy manifestations when some symptoms 
regularly prevail over the other ones in a child. For instance, there become fewer gastrointestinal 
allergy manifestations on the background of growth of respiratory disorders. In the pathogeny of 
allergic inflammation development the sensitization to allergenic molecules constitutes one of the 
main etiological factors. Therefore, to exercise control over the disease it is often insufficient to use 
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the means of baseline therapy (antileukotriene, antihistamine ones, iGCS, etc.) [5–7]. Thus, there 
arises the need to directly influence the degree of patient sensitization, which is already quite a 
complicated task. Since quite often patients are sensitized to several allergens at the same time. In 
addition the fact that with age not only the number of significant allergens, but the degree of sensi-
tization to them can be increased is important.
The efficacy of ASIT in the treatment of allergic diseases of adults and children has been 
proven and it is represented by the results of numerous randomized double-blind placebo-con-
trolled studies which have resulted in the issuance of the corresponding European and international 
non-binding Perhaps Immunotherapy that is recommended to the patients having allergic bronchial 
asthma, food allergy and manifestations of insect allergy [8–10]. The treatment of children with 
the use of immunotherapy methods is discussed in these articles [11, 12]. In addition to the method 
of sublingual allergen immunotherapy [11, 13–15]. First of all, that is connected to the issues of 
safety and administration convenience. A wide interest in the new forms of ASIT is also connected 
to the situation of “rejuvenation” of allergic pathology, i. e. appearance of symptoms characteristic 
of more advanced stages of disease in early-age children, as well as quick development of poly-
sensitization. That is why the study of the issues related to timely prescription of SLIT (as a more 
comfortable and safe form for children) and the study of its effect on coming to control allergic 
symptoms and prevention of disease progression can be regarded as one of the units of the strategic 
direction suggested by WAO. 
2. Aim
Study the efficacy of application of SLIT in children under 5 with allergic rhinitis (АR) and 
bronchial asthma (BА), sensitized to domestic house dust mite allergens.
3. Material and Methods
Studies with humans and human specimens were performed according to the Declaration 
of Helsinki and were approved by the local Bioethical Commission of the P. L. Shupyk National 
Medical Academy of Post-Graduate Education. The all patients’ parents gave their informed con-
sent to the study.
The research was carried out during 2013–2015 at the Department of Pediatrics No. 1 of 
the Shupyk National Medical Academy of Postg-Graduate Education at the premises of the pe-
diatric unit of the National Specialized Hospital for Children “OKHMATDYT” and consultative 
polyclinic for children “OKHMATDYT”. Four hundred and fifty children aged 28 months up to 
5 years were examined, out of whom for further study 125 children sensitized to house dust mites 
Dermatophagoides pteronyssinus and/or Dermatophagoides farinae were selected (according to 
skin prick tests data). 
Inclusion criteria:
1. Age from 36 months to 5 years. 
2. Clinical diagnosis АR and/or allergic BА in the intermitting or mild form/moderately 
severe form persisting – controlled, determined following ICONs criteria (2012).
3. Sensitization to domestic allergens of house dust mites D. and/or e. 
Exclusion criteria: 
1. Severe and/or uncontrolled BА.
2. Children who had undergone treatment with SLIT at the previous stages.
3. Children having counter-indications to SLIT.
SLIT was a viable alternative to the injection route, and its use in the clinical practice in 
children is justified. 20 patients underwent 2 year course of SLIT with standardized extract of sub-
ligual allergens containing a mixture of house dust mites (D. pteronyssinus and D. farinae) in the 
correlation of 1(0,175 НЕР):1(0,175 НЕР) (Diater, Spain). SLIT was started with 47 children includ-
ed into the first examination group. The part of 78 patients who refused to take SLIT (remoteness 
of allergologist and doubt as to the results) – 20 children made up the control group, as they got 
symptomatic baseline therapy under the corresponding protocols.
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Children of the first group (47) underwent SLIT under the following treatment protocol: 
intake of the drug took place on a daily basis by way of 1 spraying into the sublingual area; and 
the initial phase made up 6 months (the overall dose for a patient was 1,325–1,425 НЕР), the main-
tenance phase lasted for subsequent 18 months (overall allergen dose was on average 3,900 НЕР). 
After the first drug dose patients stayed in the clinic under the supervision for 40 minutes, for possi-
ble adverse effects to be registered, and in further the drug was administered by the child’s parents 
independently, control over possible adverse effects was exercised online by the allergologist.
Over the period of observation 4 visits a year were planned for the patients, and, if neces-
sary – an additional control visit was possible.
Skin prick tests were made following the standard methodology in accordance with the 
recommendations of the EAACI [16]. Standard inhalant panel included spring arborescent pollen, 
grass pollen and weed pollen, mold fungi, house dust mites and pet allergens (cat, dog), diagnostic 
allergen extracts of Diater S. A. (Spain) were used. A solution of histamine hydrochloride in the 
concentration of 10 mg/ml and, 0.9 % saline solution were used as positive and a negative test con-
trols respectively. Skin reaction was assessed after 15 minutes, a specimen where a 3-mm-papule 
was formed or where papule exceeded the size of the negative test control by more than 3 mm was 
considered positive. 
Molecular diagnostics using ImmunoCAP (Phadia) to identify major (r Der p1, r Der p 2) 
and minor allergens (r Der p10) of house dust mites [17, 18] was performed.
The efficacy of SLIT was assessed by a combined visual analogue scale (VAS-all) including 
6 indicators characterizing rhinitis and allergic asthma symptoms: nasal obstruction, rhinorrhea, 
nasal discharge, sneezing, nasal itch and itch of mucosa in the oral pharynx area and cough. A 
5-point gradation of VAS-all was accepted: 0 points – “0” symptoms; 1 point – minimum symp-
toms; 2 points – light symptoms; 3 points – moderately severe symptoms; 4 points – severe symp-
toms. Taking into account the age of the examined patients, graphic images were suggested – dif-
ferent variants of “smiles” for them as a visualization scale, which were then controlled by their 
parents. Besides that, during the whole examination period the parents of the patients got rec-
ommendations on additional intake of symptomatic drugs, if necessary. Additional drug intake 
was recorded in a special diary. The need for a daily drug use was assessed in the following way: 
2 points – 1 pill (5 mg)/day of anti-histamine drug, 3 points – 2 sprays (400 mkg)/day of nasal 
inhalant glucocorticosteroids, while 1 pill (4 mg/5 mg) of antileukotriene drug for children with 
allergic BA was assessed as 5 points. In the case of absence of the need for drug intake – 0 points. 
Statistical processing of the results obtained was made using the standard statistical package 
Statistical for Windows 7.0.
The details of adverse events were collected during the study in a form that recorded all 
events, irrespective of suspected relationship to the study of medication of the mild, moderate or 
serious severity.
Such examination enabled to apply a predictive algorithm of the efficacy of SLIT in chil-
dren (Table 1).
Table 1
The predictive algorithm of SLIT in children under 5 years old
Skin prick test + Skin prick test + Skin prick test +/–
r Der p1, r Der p 2 + r Der p1, r Der p 2 + r Der p1, r Der p 2 –
r Der p10 – r Der p10 + r Der p10 +/–
HIGH MIDDLE LOW
5. Results
Out of 125 children who showed positive results of skin prick test for identification of 
house dust mites D. pteronyssinus and/or D. farinae 38 (30.4 %) children were monosensitized and 
87 (69.6 %) of the examined patients showed different variants of polyvalent sensitization.
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In the group of monosensitized children 20 (52.6 %) children were traced, using molecular di-
agnostics methods, availability of sIgE specific for rDer p1, rDer p2 and absence of rDer p10, which 
enabled to prescribe SLIT with the possibility of predicting high efficacy, following the algorithm used.
In the group of polysensitized patients (87 children) molecular diagnostics was made for 
21 patients (24.1 %). Eighteen children in the group of monosensitized and 66 children in the group 
of polysensitized patients refused to undergo because they had indeterminate results. The results of 
children examination are provided in the Table 2.
Table 2
The figures for skin prick test and the data of molecular diagnostics in children with allergic rhinitis and 
allergic bronchial asthma
Groups of patients
Skin prick tests, 
average papule 
diameter in mm
rDer p 1, 
kUA/L (M±m)
rDer p 2,  
kUA/L (M±m)
rDer p 10,  
kUA/L (M±m)
Coefficient of correlation of  
“positive” prick test and  
major allergens rDer p1/rDer p 2, R
Monosensitized  
children (n–20) 7,4±4,3 13,2±9,8 30,4±12,6 0,01±0,009 0,98/0,92
Polysensitized  
children (n–21) 6,1±3,8 8,7±6,3 12,7±8,5 0,02±0,01 0,83/0,72
Comparative analysis of the results of skin prick tests involving domestic allergens of house 
dust mites D. pteronyssinus and/or D. farinae (Diater, Spain) showed that in the group of monosen-
sitized patients 19 (95 %) people out of the 20 examined ones have major allergens of house dust 
mite. Among polysensitized patients the percentage of result coincidence is lower, reaching 81 %, 
which can possibly be related to cross-responsiveness and individual skin sensitivity of children of 
that age category. Such results require further study and analysis.
Patients with confirmed sensitization to allergens of house dust mites (125 children, of 
which 41 children with high and middle efficacy prognosis for SLIT) were offered a therapy using 
sublingual allergens containing a mixture of house dust mites (D. pteronyssinus and D. farinae) 
in the correlation of 1(0,175 НЕР):1(0,175 НЕР) (Diater, Spain). SLIT was started with 47 children 
included into the first examination group. Out of 78 patients who refused to take SLIT (remoteness 
of allergologist and doubt as to the results) 20 children made up the control group, as they got symp-
tomatic baseline therapy under the corresponding protocols. 
The patients of both groups underwent the baseline therapy under the protocols. If neces-
sary, anti-histamine drugs of the second generation, inhalation beta-agonists, inhalant glucocorti-
costeroids and antileukotriene drugs were prescribed to the control respiratory symptoms.
6. Discussion
The analysis of clinical characteristics of 67 children of the 1st and the 2nd groups participat-
ing in the examination testifies to availability of considerable sensitization to house dust mites in 
both groups of patients, as confirmed by the results of molecular diagnostics and the corresponding 
clinical symptoms manifested to a different extent. A high percent of allergic rhinitis and cough 
symptoms in the children under examination attracts attention, it coinciding with the data of liter-
ature [2]. Both groups show quite a high percent: 1st group – 44.6 %, and in the 2nd group – 45 % 
of poly-sensitized children. Anyway, taking into account the fact that the results were obtained by 
the skin prick test method, and the tasks of the examination did not include assessment of possible 
adverse effects of cross-reactions – the data is slightly inflated. All the patients underwent random-
ization in correspondence with the specificity of their clinical characteristics (Table 3).
The assessment of clinical efficacy of sublingual allergen-specific immunotherapy in the first 
group of children testifies to reliable differences in VAS-all figures prior to the therapy and 6 months 
after its application. Thus, the most clearly manifested symptom “nasal obstruction” prior to the be-
ginning of the therapy was assessed as 2.3±–1.6 points, and 6 months later the figure reduced almost 
twice (1.3±–1.1); Р<0,05; while 12 and 24 months later SLIT indicator made up 0.91±0.9 and 0.34±0.5; 
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Р<0,01, correspondingly. The other indicators were also characterized by a considerable reduction, for 
example, that of cough before the therapy was 2.2±1.5 – which was clinically manifested in availability 
of moderately severe and severe cough symptoms in 60.8 % of children, in particular, in the night time 
and early in the morning, while in the observation dynamics there could be traced a reliable (Р <0.05) 
symptom regression to 1.3±1.1 6 months later, 0.7±0.3 12 months later, and 0.2±0.5 – 24 months later. 
Thus, by the end of the first year of therapy 56 % had only minimum or light symptom manifestation in 
the form of infrequent cough in the morning hours, without night awakenings, and it almost disappeared 
by the end of the 2nd year of therapy. Of interest, in our opinion, is observation and the assessment of 
nasal itch and mouth cavity mucosa itch. Out of all the children under examination there were registered 
only 2 patients with severe manifestations – 4 points under VAS-all. The cases were described for two 
children. The first one was a female, 32 months old, with a high class of sensitization to major house 
dust mites allergens (r Der p 1>100 kU\l) and availability of covalent sensitization to weed allergens. The 
second child was a female, 36 months of age, with monosensitization to major and minor house dust mite 
allergens and anamnestic data on the development of acute reactions in the form of local angioneurotic 
oedema and urticaria fever, when fish and sea food were consumed. The remaining majority (95.7 %) 
of the children under examination was not characterized by such complaints. That could possibly be 
accounted for by age specificity and availability of more manifested system reactions characteristic of 
the given age category. A considerable role in the given study goes to comparative characteristics of 
the first-group patients as compared to the second-group patients who did not undergo sublingual aller-
gen-specific immunotherapy. As of the date of the study, patients of both groups had similar indicators 
in VAS-all symptoms (Table 4). For example, the same as the symptoms of nasal obstruction and cough 
described above. Thus, as of the beginning of the therapy the indicator “cough” with the second-group 
children made up 2.6±1.3 points and did not differ significantly (P>0.05) from that of the first-group 
children – 2.2±1.5. And as of the end of the second year of the therapy there was already a significant 
difference traced in the results of the 1st and the 2nd groups: 0.2±0.1 and 2.3±0.8 points (Р<0.01). Return 
of some indicators with the 2nd-group children to almost initial condition requires further study. In the 
given study that was related to dedication of parents to the applied basic therapy which normally did 
not last more than 6–12 months (in that period reduction of VAS-all indicators “cough” to 1.5±0.7 and 
1.6±0.4 points could be traced) as well as availability of a high class of sensitization to house dust mites 
in children of the group in parallel to complexities of controlling allergen exposition, which, on the 
background of therapy denial, led to re-occurrence of disease symptoms.
Table 3
Clinical characteristics of patients of the 1st and 2nd study groups
Indicator Children of the Іst study group Children of the ІІnd study group 
Number of patients 47 20
Sex, n (%)
Male 33 (70.2) 13 (65)
Female 14 (29.8) 7 (35)
Age (M±m), years 4.11±0.83 3.8±1.2
Age limits 3–5 3–5
Clinical symptoms, n (%)*
Rhinitis 41 (87.2) 20 (100)
Rhinoconjunctivitis 4 (8.5) 3 (15)
Allergic asthma 16 (34.0) 7 (35)
Wheezing 5 (10.6) –
Upper palate itching 2 (4.2) –
Cough 41 (87.2) 17 (85)
The results of skin prick test with allergens of  
house dust mites (average diameter of papule, mm) 8.4±4.1 7.9±3.27
Number of patients with polyvalent sensitization,  
n (%) – according to the data of skin prick test 21 (44.6 %) 9 (45 %)
Note: * – symptom combination possible
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Indicators of visual analogue scale in children in the background of sublingual allergen-specific immunotherapy 




Іst group (n=47) ІІnd group (n=20)
Before  
treatment 6 months 12 months
 24 months Before treatment 6 months 12 months 24 months 
Nasal obstruction 2.3±–1.6** 1.3±–1.1* 0.91±0.9* 0.34±0.5* 2.4±1.4 2.4±1.2 2.2±0.9 2.2±0.8
Rhinorrhea 2.2±0.9** 0.5±0.5* 0.5±0.6* 0.2±0.4* 1.8±0.9 1.3±0.8 2.5±1.2 2.2±1.1
Sneezing 1.83±1.4** 0.5±0.5* 0.3±0.4* 0.34±0.5* 1.8±1.2 0.9±0.5 0.7±0.4 1.3±0.9
Nasal mucosa itch, 
mouth mucosa itch 0.2±0.9** 0.08±0.9** 0.04±0.2** 0.04±0.2** 0.04±0.2 0.04±0.2 0.04±0.2 0.04±0.2
Nasal discharge 1.8±1.3** 1.3±1.1** 0.6±0.5* 0.4±0.13* 2.2±1.1 1.5±0.7 1.6±0.5 2.2±0.9
Cough 2.2±1.5** 1.3±0.09** 0.7±0.3* 0.2±0.1* 2.6±1.3 1.5±0.7 1.6±0.4 2.3±0.8
Note: * – Р<0.05 – statistically significant differences between the first and second groups; ** – P>0.05 – statistically insignificant 
differences between the first and the second groups
One of the most important components of SLIT therapy is the possibility of its safe applica-
tion with due account of the risks of development of possible anaphylactic reactions and its tolerance 
with children. SLIT tolerance was assessed for the first-group children using a linear scale described 
above. 57.4 % of patients (and their parents) assessed SLIT tolerance as “good” and 31.9 %  as “very 
good”. Thus, the aggregate result of good and very good tolerance made up 89.3 %, which proves high 
safety of treatment and absence of serious adverse reactions. Over the whole period of observation not 
a single severe drug-related allergic/anaphylactic reaction was recorded.
7. Conclusions
The above study has shown that application of SLIT with standardized medical allergens 
in children under 5 sensitized to domestic allergens of house dust mites and having clinical man-
ifestations of allergic rhinitis and/or allergic bronchial asthma constitutes an effective and safe 
treatment method and enables to quickly (over the first 6 months of SLIT) come to control of the 
disease symptoms. The necessary condition for effective therapy is compliance with the rules of 
diagnostics which should be made following international standards using the algorithms and also 
taking into account the results of molecular diagnostics. The data of comparative analysis in the 
group of patients not undergoing SLIT has pointed to high frequency of disease symptom occur-
rence after the “lucid space” against the background of full or partial baseline therapy denial. Quite 
a number of unsolved issues related to SLIT application in early-age children require further study 
of the given therapeutic direction.
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